AVEO Pharmaceuticals, Inc. clinical trials

Acquired by LG Chem, Jan 19, 2023 · source ↗

The registry lists 35 studies whose lead sponsor is AVEO Pharmaceuticals, Inc.. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 35 of 35. All LG Chem studies →

• OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLCNot yet recruitingNCT07888075Phase 2/3

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted after AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaRecruitingNCT06064877Phase 3

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted after AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Dose Escalation Study of AV-380 in Cancer Patients With CachexiaRecruitingNCT05865535Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted after AVEO Pharmaceuticals, Inc. became part of LG Chem

• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell CarcinomaCompletedNCT04987203Phase 3

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)CompletedNCT02627963Phase 3

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedNCT03970616Phase 1/2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 1 Study of AV-380 in Healthy SubjectsCompletedNCT04815551Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell CarcinomaCompletedNCT01297244Phase 2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast CancerTerminatedNCT01745367Phase 2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCTerminatedNCT01673386Phase 2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive LabelTerminatedNCT02318368Phase 2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).CompletedNCT01076010Phase 3

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaCompletedNCT00502307Phase 2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib ProtocolsTerminatedNCT01369433Not applicable

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnNCT04100330Phase 2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaCompletedNCT01030783Phase 3

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• Protocol to Allow Continued Access of Ficlatuzumab to P05538 PatientNo longer availableNCT02090127

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line TherapyCompletedNCT01478594Phase 2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung CancerCompletedNCT01039948Phase 1/2

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid TumorsCompletedNCT01603979Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid TumorsCompletedNCT01306630Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaCompletedNCT00725634Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT01631097Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal CancersCompletedNCT00660153Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast CancerCompletedNCT00717340Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00826878Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy SubjectsCompletedNCT01316848Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy SubjectsCompletedNCT01363804Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy SubjectsCompletedNCT01363778Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver MetastasesCompletedNCT00969410Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor PatientsCompletedNCT00551850Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor MalignanciesTerminatedNCT00381654Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00563147Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem

• A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid TumorsCompletedNCT01210846Phase 1

  Sponsor listed in the registry: AVEO Pharmaceuticals, Inc. · First submitted before AVEO Pharmaceuticals, Inc. became part of LG Chem